Literature DB >> 32189161

Female Genital Mutilation/Cutting as Grounds for Asylum Requests in the US: An Analysis of More than 100 Cases.

Katherine Wikholm1, Ranit Mishori2, Deborah Ottenheimer3, Valeriy Korostyshevskiy4, Rebecca Reingold5, Colin Wikholm6, Kathryn Hampton7.   

Abstract

Female Genital Mutilation or Cutting (FGM/C) is a human rights violation used to claim asylum in the US. We sought to understand the nature of these asylum requests. Analysis of 121 FGM/C-focused medical affidavits, and 132 legal case reports. Of 119 eligible affidavits analyzed, 84% were reportedly cut: 4.6% Type I, 84.6% Type II, 16.5% Type III. Average age: 9. Reported acute effects: bleeding (76.3%), infection (27.6%), shock (6.7%), broken bones (2.7%), and hospitalization (2.7%). Reported chronic issues: intercourse difficulty (81.7%), pregnancy complications (54.2%), chronic pain (42.4%), scarring (37.3%), urinary difficulty (31.8%). Psychological consequences included PTSD (72.4%), depression (65.9%), anxiety (51.1%), and lack of trust (10.1%). Co-occurring abuses included domestic violence (62.4%), forced marriage (46%), rape (33.3%), torture (33.3%), child marriage (31.3%), assault due to LGBTQ + status (2.9%). Women claiming asylum based on FGM/C report high rates of chronic health issues. Their histories suggest FGM/C co-occurs with other forms of gender-based violence.

Entities:  

Keywords:  Asylum; Asylum seekers; Female circumcision; Female genital cutting/mutilation; Forensic evaluation; Gender based violence?; Human rights; Medico-legal; Violence against women

Mesh:

Year:  2020        PMID: 32189161     DOI: 10.1007/s10903-020-00994-8

Source DB:  PubMed          Journal:  J Immigr Minor Health        ISSN: 1557-1912


  1 in total

1.  The global prevalence of female genital mutilation/cutting: A systematic review and meta-analysis of national, regional, facility, and school-based studies.

Authors:  Leen Farouki; Zeinab El-Dirani; Sawsan Abdulrahim; Christelle Akl; Chaza Akik; Stephen J McCall
Journal:  PLoS Med       Date:  2022-09-01       Impact factor: 11.613

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.